Abstract: A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropylmethylcellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP). The compositions having improved solubility, hence bioavailability, in the small intestine; Processes for testing such compositions, and methods of using such compositions. The compositions comprise the basic drug, zwitterion, or salt and one or more of the aforementioned polymers. The invention further relates to a method for increasing the bioavailability of a basic or a zwitterionic drug comprising co-administering the basic drug, the zwitterionic drug, or the salt, with one or more of the aforementioned polymers.
Type:
Grant
Filed:
January 31, 2000
Date of Patent:
April 15, 2003
Assignee:
Pfizer Inc
Inventors:
William J. Curatolo, James A. S. Nightingale, Ravi M. Shanker, Steven C. Sutton
Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 55080. This novel antibiotic is useful as an anticoccidial in poultry, in the prevention and treatment of swine dysentery and as a growth promotant in cattle and swine.
Type:
Grant
Filed:
December 6, 1994
Date of Patent:
February 27, 1996
Assignee:
Pfizer Inc.
Inventors:
Walter P. Cullen, John P. Dirlam, Hiroshi Maeda, Junsuke Tone